Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Randomized Controlled Trial
. 2025 Jun 20;17(13):2064.
doi: 10.3390/nu17132064.

Curcumin Supplementation Improves Gastrointestinal Symptoms in Women with Severe Obesity: A Double-Blind, Randomized, Placebo-Controlled Trial-A Pilot Study

Fabiana Martins Kattah  1 , Nayra Figueiredo  2 , Kamilla Kenned Bezerra  1 , Emilly Santos Oliveira  1 , Cinara Costa de Melo  2 , Gislene Batista Lima  1 , Jocélia Paula Rocha Cavalcante  1 , Beatriz Bacheschi do Carmo Benetti  2 , Glaucia Carielo Lima  1 , João Felipe Mota  1   2 , Flávia Campos Corgosinho  1   2
Affiliations
Randomized Controlled Trial

Curcumin Supplementation Improves Gastrointestinal Symptoms in Women with Severe Obesity: A Double-Blind, Randomized, Placebo-Controlled Trial-A Pilot Study

Fabiana Martins Kattah et al. Nutrients. .

Abstract

Gastrointestinal symptoms, including reflux, bloating, dyspepsia, stomach pain, and altered bowel patterns, are commonly reported in individuals with severe obesity and may significantly impact quality of life. Background/Objectives: Curcumin, a bioactive compound found in turmeric (Curcuma longa L.), possesses anti-inflammatory and antioxidant properties and has been investigated for its potential role in gastrointestinal health. However, its effects in individuals with severe obesity remain unclear. Methods: This double-blind, placebo-controlled clinical trial aimed to evaluate the effect of curcumin supplementation on gastrointestinal symptoms in women with severe obesity. Thirty-one women with a body mass index (BMI) ≥ 40 kg/m2 undergoing bariatric surgery were randomized to receive either 1500 mg of curcumin (98.75%) or a placebo (1500 mg corn starch) daily for 13 weeks. Gastrointestinal symptoms were assessed using the Gastrointestinal Symptom Rating Scale (GSRS), and stool consistency was assessed using the Bristol Stool Scale. Anthropometric measurements were also collected. Results: Participants had an average age of 33.1 ± 8 years and a BMI of 45.6 ± 3.31 kg/m2. No differences were observed between groups at baseline. At the end of the study, the curcumin group showed a significant reduction in the GSRS's total score compared to the placebo group (p = 0.002), with improvements in eructation (p = 0.011) and constipation (p = 0.007). Additionally, the curcumin group showed reduced BMI (p = 0.019) and neck circumference (p = 0.042). Conclusions: These findings suggest that curcumin supplementation may alleviate some gastrointestinal symptoms and improve anthropometric measures in women with severe obesity, providing a potential dietary strategy.

Keywords: gastrointestinal symptoms; stool consistency; turmeric.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflicts of interest.

Figures

Figure 1
Figure 1
Study design.
Figure 2
Figure 2
CONSORT flowchart diagram of clinical trial.
See this image and copyright information in PMC

References

    1. Rubino F., Cummings D.E., Eckel R.H., Cohen R.V., Wilding J.P.H., Brown W.A., Stanford F.C., Batterham R.L., Farooqi I.S., Farpour-Lamb N.J., et al. Definition and diagnostic criteria of clinical obesity. Lancet Diabetes Endocrinol. 2025;13:221–262. doi: 10.1016/S2213-8587(24)00316-4. - DOI - PMC - PubMed
    1. Steenackers N., Eksteen G., Wauters L., Augustijns P., Van der Schueren B., Vanuytsel T., Matthys C. Understanding the gastrointestinal tract in obesity: From gut motility patterns to enzyme secretion. Neurogastroenterol. Motil. 2024;36:e14758. doi: 10.1111/nmo.14758. - DOI - PubMed
    1. Poylin V., Serrot F.J., Madoff R.D., Ikramuddin S., Mellgren A., Lowry A.C., Melton G.B. Obesity and bariatric surgery: A systematic review of associations with defecatory dysfunction. Color. Dis. 2011;13:e92–e103. doi: 10.1111/j.1463-1318.2011.02584.x. - DOI - PubMed
    1. Massier L., Chakaroun R., Tabei S., Crane A., Didt K.D., Fallmann J., von Bergen M., Haange S.-B., Heyne H., Stumvoll M., et al. Adipose tissue derived bacteria are associated with inflammation in obesity and type 2 diabetes. Gut. 2020;69:1796–1806. doi: 10.1136/gutjnl-2019-320118. - DOI - PubMed
    1. Hood M.M., Corsica J., Bradley L., Wilson R., Chirinos D.A., Vivo A. Managing severe obesity: Understanding and improving treatment adherence in bariatric surgery. J. Behav. Med. 2016;39:1092–1103. doi: 10.1007/s10865-016-9772-4. - DOI - PubMed

Publication types

LinkOut - more resources